Menu Search
Equities

Predictive Oncology Inc

S1K:MUN

Predictive Oncology Inc

Actions
  • Price (EUR)1.64
  • Today's Change0.06 / 3.80%
  • Shares traded800.00
  • 1 Year change-37.52%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 08:34 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.

  • Revenue in USD (TTM)1.78m
  • Net income in USD-13.98m
  • Incorporated2013
  • Employees34.00
  • Location
    Predictive Oncology Inc91 43RD STREET, SUITE 110PITTSBURGH 15201United StatesUSA
  • Phone+1 (412) 432-1500
  • Fax+1 (651) 379-5024
  • Websitehttps://predictive-oncology.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.